


## Data Sheet

[WWW.UREIKO-CHEM.COM](http://WWW.UREIKO-CHEM.COM)

Global Supplier of Chemical Probes, Inhibitors & Agonists

<b>Product Name</b>	:BMS-1166-N-piperidine-CO-N-piperazine
<b>Cat.No.</b>	:URK-V2492
<b>CAS No.</b>	:2447066-14-8
<b>Molecular Formula</b>	:C41H43ClN4O5
<b>Molecular Weight</b>	:707.26
<b>Target</b>	:
<b>Solubility</b>	:



### Biological Activity

BMS-1166-N-piperidine-CO-N-piperazine contains PD-1/PD-L1 ligand and PROTAC linker. This compound has exhibited high potency and selectivity against PD-1/PD-L1 pathway.

PD-1 (programmed cell death protein 1) is a receptor found on immune cells, while PD-L1 (programmed death-ligand 1) is a ligand on tumor cells. When PD-1 binds to PD-L1, it inhibits the activity of immune cells, leading to immune evasion by the tumor. BMS-1166-N-piperidine-CO-N-piperazine works by selectively binding to PD-L1 and inducing PD-L1 degradation through the ubiquitin-proteasome system. This leads to the reactivation of immune cells and enhances their ability to kill tumor cells.

The development of BMS-1166-N-piperidine-CO-N-piperazine is a significant breakthrough in cancer treatment. By targeting the PD-1/PD-L1 pathway, it has shown promising results in preclinical studies for the treatment of different types of cancer, including melanoma, lung, and bladder cancer.

### References

1. Wang L, et al. Mol Cell. 2020;77(5):1082-93.
2. Zhou Q, et al. Nat Commun. 2021;12(1):1-13.
3. Xu J, et al. OncoTargets Ther. 2021;14:2325.
4. Zhao M, et al. Front Oncol. 2020;10:580026.

*Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!*

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

[JACK@UREIKO-CHEM.COM](mailto:JACK@UREIKO-CHEM.COM)